ENFERMEDADES DIGESTIVAS
Hospital Universitario Virgen Macarena
Sevilla, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario Virgen Macarena (10)
2022
-
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Frontiers in Medicine, Vol. 9
-
Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU
Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
2021
-
European registry on helicobacter pylori management: Effectiveness of first and second-line treatment in Spain
Antibiotics, Vol. 10, Núm. 1, pp. 1-15
2020
-
Clinical validation of risk scoring systems to predict risk of delayed bleeding after EMR of large colorectal lesions
Gastrointestinal Endoscopy, Vol. 91, Núm. 4, pp. 868-878.e3
-
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry
Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616
2019
-
Prevalence and Factors Associated with Fatigue in Patients with Inflammatory Bowel Disease: A Multicentre Study
Journal of Crohn's and Colitis, Vol. 13, Núm. 8, pp. 996-1002
2017
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
2015
-
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: The OPTRICON study
Alimentary Pharmacology and Therapeutics, Vol. 41, Núm. 6, pp. 581-589